Gemcitabine Monotherapy as Second-Line Treatment in Cisplatin-Refractory Transitional Cell Carcinoma – Prognostic Factors for Response and Improvement of Quality of Life

Publisher： Karger

E-ISSN： 2296-5262|25|1|47-52

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.25, Iss.1, 2002-03, pp. : 47-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Outcome of Paclitaxel and Carboplatin as Second-Line Chemotherapy for Advanced Urothelial Carcinoma Resistant to First-Line Therapy with Gemcitabine and Cisplatin

By  

Urologia Internationalis, Vol. 92, Iss. 2, 2013-11 ,pp. : 180-185

Karger

Access to resources Recommend Favorite

Sunitinib in Patients with Cisplatin-Refractory Germ Cell Tumors

By  

Oncology Research and Treatment, Vol. 35, Iss. 7-8, 2012-07 ,pp. : 455-456

Karger

Access to resources Recommend Favorite

PSA and Second-Line Therapy of Hormone Refractory Prostate Carcinoma

By  

Urologia Internationalis, Vol. 66, Iss. 3, 2001-04 ,pp. : 131-134

Karger

Access to resources Recommend Favorite

Intravesical Gemcitabine in BCG-Refractory T1G3 Transitional Cell Carcinoma of the Bladder: A Pilot Study

By  

Urologia Internationalis, Vol. 76, Iss. 2, 2006-02 ,pp. : 106-111

Karger

Access to resources Recommend Favorite

Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 39-45

Karger

Access to resources Recommend Favorite